Oncology
Endothelin Antagonist Keeps Patients with Hormone Refractory Prostate Cancer Alive Longer
Nicholas James
Gordon McVie
REFERENCE: Abstract: 3LB (Presidential Session), ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
NICHOLAS JAMES, Birmingham University
COMMENT: GORDON MCVIE, European Institute of Oncology, Milan
A new drug has improved overall survival among patients with hormone resistant prostate cancer. The endothelin A antagonist ZD4054 was investigated in a placebo-controlled trial among 300 patients whose hormone-resistant prostate cancer had metastasized to bone.
NICHOLAS JAMES, Birmingham University
COMMENT: GORDON MCVIE, European Institute of Oncology, Milan
A new drug has improved overall survival among patients with hormone resistant prostate cancer. The endothelin A antagonist ZD4054 was investigated in a placebo-controlled trial among 300 patients whose hormone-resistant prostate cancer had metastasized to bone.
Jacek Jassem
David Cameron
EIxabepilone With Capecitabine: New Treatment Option For Patients Resistant to Anthracyclines and Taxanes?
REFERENCE: Abstract: 2101, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
JACEK JASSEM, Medical University of Gdansk
COMMENT: DAVID CAMERON, UK National Cancer Research Network, Leeds
A combination of capecitabine and the anti-resistance agent, ixabepilone, has demonstrated a benefit over capecitabine alone for patients with breast cancer who develop resistance to anthracycline and taxane therapy.
JACEK JASSEM, Medical University of Gdansk
COMMENT: DAVID CAMERON, UK National Cancer Research Network, Leeds
A combination of capecitabine and the anti-resistance agent, ixabepilone, has demonstrated a benefit over capecitabine alone for patients with breast cancer who develop resistance to anthracycline and taxane therapy.
Anna Pavlick
Steven Novick
Oblimersen: Making Sense in Malignant Melanoma And Chronic Lymphocytic Leukemia?
REFERENCE: Abstracts: 7000 & 6004, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
ANNA PAVLICK, New York University Cancer Institute
STEVEN NOVICK, Genta Incorporated, Berkeley Heights, NJ
New data on the antisense drug oblimersen combined with standard chemotherapy in two different clinical settings: malignant melanoma, and chronic lymphocytic leukemia were presented at the ECCO conference.
ANNA PAVLICK, New York University Cancer Institute
STEVEN NOVICK, Genta Incorporated, Berkeley Heights, NJ
New data on the antisense drug oblimersen combined with standard chemotherapy in two different clinical settings: malignant melanoma, and chronic lymphocytic leukemia were presented at the ECCO conference.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
Similar Interviews
Post a comment
Health For All 30 Years After Alma Ata? Mental Health And War»
AliaIbrahim Zai, Egbert Sondorp, Gill Walt, Lucy Gilson, Ravi Narayan, Richard Horton, Vikram Patel, Willem Van De Put
Two important symposia have been held in London to discuss healthcare issues posing significant dilemmas to world leaders in the 21st Century. "The Future of Primary Health Care" was attended by public health experts from around the Globe to assess the best options for improving primary health care in the future. It was held on the 30th anniversary of the Alma Ata Declaration made in 1977 which was intended as a blueprint for health provision and identified primary health care as the means through which the global goal of "Health for All" could be achieved. The second meeting, on "Mental Health in Fragile States", was held to raise the profile of mental health care in zones where conflict has taken place or is still happening. Analyses of the key issues and how to deal with them effectively were discussed by top experts from the London School of Hygiene and Tropical Medicine and associated organisations. Peter Goodwin attended both meetings and talked with some of the key speakers.AliaIbrahim Zai, Egbert Sondorp, Gill Walt, Lucy Gilson, Ravi Narayan, Richard Horton, Vikram Patel, Willem Van De Put
LSHTM Audio News: British Association Special Edition»
Astrid Fletcher, Jo Lines, Sari Kovats, Colin Sutherland, Michel Coleman
Peter Goodwin hears from London School of Hygiene and Tropical Medicine experts speaking at the annual science festival of the British Association for the Advancement of Science held in Liverpool, September 6-10, 2008, and from recent scientific publications on: the health impact of global warming, a tropical virus reaching temperate zones, inequalities in cancer outcomes, how eating oily fish can save your eyesight, and free internet publishing scientific journals.Astrid Fletcher, Jo Lines, Sari Kovats, Colin Sutherland, Michel Coleman
© 2008 Audio Medica - Medical Audio News Interviews & Podcasts. 
[...] over capecitabine alone for patients with breast cancer who develop …article continues at admin brought to you by cancer.medtrials.info and [...]
[...] post by admin delivered by Medtrials and [...]